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Part I: Executive summary 
1. Background information 
a. Conceptual approach of health services research 
In Germany, just about 20 years ago, ‘Versorgungsforschung’ (Health Services Re-
search/HSR) was acknowledged as an independent field of research rooted in the tradi-
tions of medical sociology and health care systems research with close connections to 
clinical research and public health (Pfaff and Kaiser 2006).   
Whilst clinical research is focused on generating either evidence on efficacy in a clinical 
setting or in providing early evidence on the ‘added value’ of a technology in routine 
care settings, HSR targets assessment, analysis, prognosis, appraisal, development and 
evaluation of routine care per se. In contrast to public health, which has a strongly pre-
ventive orientation and often targets non-medical population-based intervention strate-
gies, HSR focuses on the management of distinct indications respectively the manage-
ment of distinct patient populations by predominantly medical means. However, a clear 
distinction between these related research areas does not exist and the border is fluent 
(Raspe, Pfaff et al. 2010).  
HSR is multidisciplinary in nature and broad in scope: it comprises all kinds of evi-
dence generation on the ‘use, costs, quality, accessibility, delivery, organization, financ-
ing, and outcomes of health care services’ with the purpose of creating in-depth under-
standing of the structures, processes and effects of health care (Lohr and Steinwachs 
2002). In the German context, HSR has been characterized by its population focus, the 
high level of patient orientation, the context-related research perspective, the pursuit of 
cross-sectional solutions, the overarching aim of improving the current status quo and 
the self-commitment to provide application-oriented, evidence-based support to policy 
decision makers (Pfaff and Schrappe 2011). 
In consequence, the spectrum of HSR studies is manifold. It incorporates descriptive 
analyses of the current health care system, the evaluation of determinants of health care 
utilization, the conceptual development of health care interventions, the identification of 
key success criteria for innovative care strategies within real-world settings, the elabora-
tion of best practice examples as well as theoretical groundwork on the operationaliza-
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tion of deciding factors (e.g. ‘equity’, ‘added value’, etc.)(Nellesen-Martens, Edmund et 
al. 2014).  
Corresponding research can address the structural framework of health care provision 
(input), the interactive process of health care service delivery (throughput), the interme-
diate results of health care service utilization (output) as well as long-term effects (out-
come). According to the recent concept paper by Schrappe and Pfaff, the outcome is the 
most important of these four related but to some extent independent elements of a health 
care system. Thus, their current definition of HSR is as follows (Schrappe and Pfaff 
2016): 
‘HSR is a cross-professional field of research which – surmising from a patient and 
population perspective and considering complex context conditions – investigates health 
care structures and processes, describes outcomes on the level of daily routine care and 
evaluates complex interventions to improve health care.’ 
Owing to the long-lasting perspective and the mission to evolve health care in daily rou-
tine, randomized trials are sparse in HSR (Greiner, Witte et al. 2014), and observational 
studies are the main source of information (Pfaff, Glaeske et al. 2009). These observa-
tional data predominantly stem from primary data sources such as patient and popula-
tion cohorts or disease-specific registries. More recently, there has been growing inter-
est in using secondary data from claims to the Statutory Health Insurance (SHI) funds 
for HSR (Schubert, Köster et al. 2008, Müller and Rothgang 2015). 
 
b. Status quo of claims data analysis in Germany 
SHI claims data are the major contributor to secondary data, which are defined as any 
data that are routinely collected in the health care sector without a primary interest in 
their scientific evaluation (Swart and Ihle 2005). SHI claims data are mainly collected 
for the purpose of reimbursement and refer to insurants, service providers and in some 
parts to employers. Given this primarily documentation-oriented routine collection, 
claims data-based HSR can be interpreted as any kind of analyses of SHI data beyond 
the bare documentation purpose itself. 
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The content and scope of claims data are regulated by Volume V of the German Social 
Insurance Code (SGB V) and include in- and outpatient hospital care, outpatient physi-
cian care (general practitioner and medical specialist), drug prescriptions, rehabilitation, 
non-physician services (e.g. physiotherapy, occupational therapy, speech therapy) and 
medical aids. In addition to SHI itself, information on compulsory long-term care insur-
ance (SGB XI) is also often augmented in the analyses. 
Health insurance is mandatory in Germany, with about 80% of the resident population 
being insured within the SHI system. Thus, the German HSR movement soon recog-
nized the potential of claims data for epidemiological and health economic research 
(Müller and Rothgang 2015). Over the last two decades, claims data analyses have be-
come a valuable source of information, with a considerable increase in significance after 
the introduction of the morbidity-oriented risk structures scheme in 2009. Most contri-
butions to the field are empirical, but a growing number of methodological applications 
are also found (Kreis, Neubauer et al. 2016).  
To ensure and improve the methodological quality of claims data-based research, na-
tional guidelines for their conduct have been agreed (Good practice secondary data 
analysis/GPS) (Swart, Gothe et al. 2015). Subsequently, a uniform reporting standard, 
the STROSA (STandardisierte BerichtsROutine für SekundärdatenAnalysen) oriented at 
the STROBE (STrengthening the Reporting of OBservational studies in Epidemiology) 
concept for epidemiological studies, has been proposed (Swart, Bitzer et al. 2016). 
Moreover, ambiguous terms regarding the definition of ‘health care utilization’ have 
been identified – inclusive of suggestions on which one to apply (Schwarzkopf, Menn et 
al. 2012). This can be seen as an initial step towards a uniform terminology in claims 
data analyses. Finally, the AGENS  (Arbeitsgruppe Erhebung und Nutzung von 
Sekundärdaten) has established itself as a national platform for claims data analysts for 
methodological discussions on strategies for dealing with claim data-specific challeng-
es.  
 
c. Contribution of this ‘Habilitationsschrift’ to the scientific discussion 
This ‘Habilitationsschrift’ aims to further contribute to the ongoing discussion on the 
perspectives of claims data analyses as a cornerstone of HSR in Germany in a two-fold 
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manner. First, it introduces illustrative examples of empirical applications to shed light 
on the manifold potentials of claims data-based HSR. Second, based on conceptual 
work, it critically appraises the usefulness of claims data-based studies for decision sup-
port in distinct aspects of HSR. 
The ‘Habilitationsschrift’ is structured as follows: Chapter 2 portrays current standard 
procedures and innovative methodological advances that deal with prominent challeng-
es in the design of claims data-based studies. With the support of illustrative examples, 
Chapter 3 elucidates promising fields of application for claims-data based HSR. Subse-
quently, Chapter 4 elaborates some conceptual thoughts on the prospects of claims data 
as a source for evidence generation in HSR. Each chapter culminates in a brief appraisal 
of the presented findings. As a complement, the final Chapter 5 provides concluding 
remarks on future perspectives for claims data-based HSR in Germany. 
  
 
2. Conceptual challenges in the design of claims data-based 
studies 
a. Inference in non-randomized-large scale data sets 
Owing to their observational nature, the well-known issues of interpreting the results of 
non-randomized studies (Rovithis 2013, Martin 2014) apply to claims data as well. In 
consequence, established techniques for the analysis of observational data have been 
adopted from epidemiology and public health. These methods include multivariate re-
gression analysis (for an application, see Walter et al. 2018 who performed a stratified 
comparison of different closing techniques in femoral cardiac catheterization interven-
tions (Walter, Brandes et al. 2017), propensity score techniques ((Caliendo and Ko-
peinig 2008, Austin 2011); for an application, see Witt et al. who addressed the survival 
effects of a disease management programme via propensity score matching in open co-
horts (Witt, Leidl et al. 2014)) and entropy balancing ((Hainmueller 2012); for an appli-
cation, see Hofer et al. who applied a difference-in-difference approach to evaluate a 
tele-monitoring intervention among chronic obstructive pulmonary disease (COPD) pa-
tients (Hofer, Achelrod et al. 2016)).  
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Apart from general methodological developments in these fields, just recently, claims 
data-specific applications have been proposed for propensity scores. Braun et al. de-
signed an algorithm that accounts for the inaccuracy of billing codes (Braun, Gorfine et 
al. 2017), Schneeweis et al. suggested an automated technique for propensity weighting 
(Schneeweiss, Rassen et al. 2009, Wyss, Fireman et al. 2018) and Karim et al. com-
bined high dimensional propensity scores with machine learning (Karim, Pang et al. 
2018).  
Usually, each single study decides on just one of these techniques to achieve ‘ex post’ 
randomization. Thus, the quantitative effect of the chosen method on resulting effect 
estimates is not well understood. At least for the cost side, we could partially close this 
knowledge gap. A comparison of multivariate regression, matched pairs (age and gen-
der) and 1:2 Greedy propensity score matching revealed substantially differing esti-
mates for mean annual per capita SHI expenditures in COPD patients with and without 
ischaemic heart disease (IHD)1 (Schwarzkopf, Wacker et al. 2016). However, when it 
comes to judging treatment effects in groups with non-random treatment assignment, a 
comprehensive comparison of the various strategies at hand is still pending. Thus, it re-
mains a case-by-case decision for the researcher as to how to approximate the ‘true’ in-
tervention effect. 
In addition to the question of how to best possibly achieve quasi-randomization among 
the distinct groups of comparisons, the interpretation of effect sizes is not necessarily 
straightforward. Owing to large sample sizes, even small differences become statistical-
ly significant, even though their clinical relevance might be questionable (Lin, Jr et al. 
2013). Our 2014 comparison of comorbidity burden in individuals with and without 
dementia revealed a significantly increased likelihood of comorbid cardiac arrhythmia 
in dementia patients compared with elderly control subjects without dementia, but the 
prevalence differed by only 0.7% (28.8% vs. 28.1%) (Bauer, Schwarzkopf et al. 2014). 
Regarding the costs of care, a recent master thesis at our institute identified comorbid 
COPD as a significant cost-driving factor in interstitial lung disease (ILD) but, given 
baseline costs of €4523, the resulting additional €78 (+1.7%) might not be of economic 
relevance (Frank 2018).  
                                                          
1 Propensity score not included in final paper. 
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Against this background, relying on p-values alone seems fallacious. Instead, reporting 
of relative effects (e.g. percentages), mirroring against – if available – minimum im-
portant clinical differences, and a tentative interpretation is paramount to avoid the 
over-interpretation of statistically significant results. 
 
b. Internal validation of diagnostic information 
In general, claims data-based studies aim to shed light on health care service provision 
in patient populations that are characterized by a distinct disease. To select this study 
population, disease incidence/prevalence is operationalized via specific diagnostic 
ICD10 and ICD9 codes.  
The accuracy of these codes is open to speculation, as there is always a risk of coding 
errors (O'Malley, Cook et al. 2005). Moreover, the current coding system is sometimes 
not detailed enough to allow a precise distinction for different subtypes of a disease. 
Regarding ILDs, for example, the different subtypes of fibrosing ILDs cannot be disen-
tangled (Schwarzkopf, Witt et al. 2018) and, for lung cancer, even the basic distinction 
between small cell lung cancer and non-small cell lung cancer is not feasible 
(Schwarzkopf, Wacker et al. 2015). Finally, there is the non-quantifiable issue of strate-
gic coding, which introduces a bias towards more frequent coding of diagnoses that 
have a positive impact on remuneration (Reinhold, Thierfelder et al. 2009).  
To enhance the internal validity of documented diagnoses, several strategies have been 
recommended that mitigate the risk of ‘false positives’ (Hoffmann, Andersohn et al. 
2008, Schubert, Ihle et al. 2010, Hartmann, Weidmann et al. 2016). All these techniques 
do not rely on one single diagnosis but require distinct patterns of diagnoses to classify 
a condition as present. The most prominent example of these approaches is the so-called 
M2Q criterion, which is used for the Hierarchical Morbidity Groups of Germany’s mor-
bidity-oriented risk structures scheme. Here, a condition (e.g. COPD) is only considered 
prevalent if an insurant is diagnosed in at least two different quarters of a year or if s/he 
received at least one inpatient diagnosis (German Federal Insurance Office 2008).  
Additionally, cross-validation concepts that aim to validate the presence of a disease via 
a combined look at (in- and outpatient) diagnoses, drug prescriptions and the conduct of 
distinct medical examinations were recommended. E.g. for type II diabetes, the ‘Hauner 
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criteria’ combine diabetes diagnoses with prescriptions for anti-diabetic drugs and blood 
glucose measurement (Hauner, Köster et al. 2007). Moreover, a ranking of diagnoses 
followed by prospective validation – defined as a distinct repetition pattern of diagnoses 
in a pre-defined timeframe after the first diagnosis – can be applied.  
As example might serve the selection of patients with ILD in the study by Schwarzkopf 
et al. (Schwarzkopf, Witt et al. 2018). Starting with 454,254 diagnosed individuals2, 
first those without an inpatient or without an outpatient diagnosis by a relevant medical 
specialist (pulmonologist, internal specialist, rheumatologist) were excluded. Then, in-
surants without a relevant diagnostic procedure and those with implausible diagnostic 
patterns (e.g. ‘exclusion of’ diagnosis after ‘confirmed’ diagnosis) were dropped. In do-
ing so, 73,167 ILD patients remained. After further omission of individuals with incom-
plete demographic information or with interrupted enrolment, the remainder were split 
into 21,543 prevalent and 36,821 incident cases. The latter were finally prospectively 
validated by requiring further ILD diagnoses across all quarters of the patients’ individ-
ual follow-up period, allowing only one diagnosis-free quarter. Thus, 21,581 remained. 
All these strategies have the disadvantage of increasing the share of ‘false-negative’ 
classifications because they might be too restrictive to address less severe cases. E.g. 
not every individual with diabetes requires medical treatment (Schwarzkopf, Holle et al. 
2017). Thus, Schubert et al. suggested a patient grouping into ‘confirmed’, ‘probable’ 
and ‘questionable’ cases, depending on the extent and stringency of the inclusion crite-
ria fulfilled (Schubert, Ihle et al. 2010). However, even this idea of creating an upper 
and a lower threshold is of limited use when acute conditions with short disease dura-
tion are investigated. 
 
c. Quantification of economic burden 
Health economic theory defines cost as a monetary valuation of resource utilization, 
which is not necessarily linked to cash flow, and distinguishes direct medical (resource 
consumption within the health care sector), direct non-medical (resource consumption 
                                                          
2 ICD10 codes applied were J84.1 for ‘Idiopathic Interstitial Pneumonia’, J84.0, J84.8, J84.9, D48.1 for 
‘Other Fibrosing ILDs’, D86.0–D86.9 for ‘Sarcoidosis’, J70.2–J70.4 for ‘Drug-associated ILD’, J62.0–
J62.8 and J63.0–J63.8 for ‘Pneumoconiosis’, J70.1 for ‘Radiation-associated Pneumonitis’, J82 for ‘Eo-
sinophilic Pneumonia’, J67.9 for ‘Hypersensitivity Pneumonitis’ and J99.1 for ‘Connective Tissue-
associated ILD’. 
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outside the health care sector) and indirect (productivity loss) costs of health care 
(Brouwer, Rutten et al. 2001).  
Claims data are collected for the purpose of reimbursement within the SHI system and 
thus reflect just a - nevertheless meaningful - section of direct costs. In contrast, they 
disregard crucial cost components borne by the patients or other parts of society as well 
as indirect costs owing to working days lost. This narrow payer perspective has its own 
reasons for being, but health economic standards recommend the more comprehensive 
‘societal perspective’ to support policy decision making (von der Schulenburg, Greiner 
et al. 2008, Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen 2017).  
Apart from a time lag between resource consumption and billing (Reinhold, Andersohn 
et al. 2011), two crucial challenges are inherent in claims data. First, services are gener-
ally reimbursed on an aggregated level that reflects a lump sum for a bundle of distinct 
components. In the inpatient sector, a diagnosis related group (DRG) accounts for all 
procedures during a patient’s stay. Outpatient physician care is billed by quarter-
specific account cases that summarize the entire service provision given to a patient dur-
ing a quarter of the year, irrespective of the number of patient–physician contacts. HSR 
is often interested in a more granular view on distinct components of service provision 
(e.g. diagnostic costs only), which cannot be precisely disentangled. All the more chal-
lenging is the fact that services and diagnoses are not linked with each other. This is a 
substantial issue for cost of illness analyses per se because claims data reflect expendi-
tures per patient rather than the disease-specific cost of care.  
To best possibly disentangle related and unrelated expenditures, many claims data stud-
ies rely on excess cost approaches that compare a population with a distinct condition 
against a population without (Akobundu, Ju et al. 2006). The spending differences ob-
served - after adjustment for crucial covariates - are assumed to be disease related. 
Referring to the example of COPD patients with and without IHD, we identfied both 
cohorts via M2Q criterion for the year 2011 and then assessed 2012 SHI expenditures 
(Schwarzkopf, Wacker et al. 2016). Here, the matched pair analyses revealed an excess 
of ca. €1500 in mean annual per capita costs for the cohort with comorbid IHD. This 
additional spending was mainly triggered by hospitalizations. 
However, in absence of a control group, the only means of reflecting cost of illness is a 
summation of disease-specific spending (Akobundu, Ju et al. 2006). Here, the 
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classification of services as disease related opens the scope for discretionary decisions. 
For example, we developed two alternative strategies to reflect lung cancer-specific cost 
of care (Schwarzkopf, Wacker et al. 2015). The narrow definition (‘main analysis’) ac-
counted for spending on traditional chemotherapeutics, monoclonal antibodies, inpatient 
treatment with a principal diagnosis of lung cancer, rehabilitation stays with lung cancer 
as the reason for admission and outpatient physician contacts with at least one ‘con-
firmed’ diagnosis of lung cancer. Our ‘broad’ definition (sensitivity analysis) amended 
this spectrum by hospitalizations with a secondary diagnosis of lung cancer and by 
chemo- and radiotherapy-relevant co-medication (antiemetic preparations, antibiotics, 
bisphosphonates, anti-anaemic preparations and mesna). Given the lack of a link be-
tween diagnoses and related services, both operationalizations to some extent imprecise. 
Moreover, the sum disease-specific approach might not fully capture costs of illness. 
The presence of a distinct condition most probably impacts on the costs of care in not 
per se disease-associated situations, because morbidity affects treatment options. This 
hypothesis was supported by an add-on analysis in the COPD example, which quanti-
fied expenditures for IHD-related drugs and hospitalizations owing to IHD. For both 
sectors, this disease-specific summation remained substantially below the sector-
specific excess costs (inpatient: €819 vs. €65, drugs €297 vs. €120) (Schwarzkopf, 
Wacker et al. 2016). Therefore, the excess cost method, which does not intend to explic-
itly model disease-related expenditures, seems to be the method of choice and should be 
implemented whenever applicable. 
 
 
3. Fields of application for claims data-based health services re-
search 
a. Health impact of comorbidity burden 
The presence of distinct comorbid conditions influences treatment options, clinical 
prognosis and management requirements. Thus, detailed information on comorbidity 
burden is required to judge the health care service needs of a patient population com-
prehensively. 
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In this regard, the first descriptive step is a detailed assessment of comorbidity burden in 
the population of interest. Given that ICD10 codes enable an almost unlimited variety of 
diagnoses, setting a focus on distinct conditions seems paramount. To do so, several 
claims data-based algorithms have been suggested (Charlson, Pompei et al. 1987, 
Incalzi, Capparella et al. 1997, Elixhauser, Steiner et al. 1998, Gagne, Glynn et al. 
2011). These generic indices by trend disregard certain conditions that are either highly 
prevalent or of particular clinical interest in distinct diseases (Bauer, Schwarzkopf et al. 
2014, Schwarzkopf, Witt et al. 2018). Therefore, an indication-oriented case-by-case 
adaptation is more likely to reflect the care-relevant burden of disease. 
Using the example of ILD (Schwarzkopf, Witt et al. 2018), the comorbidities included 
in the Elixhauser comorbidity index include some ILD subtypes within the domain 
‘chronic pulmonary disease’, but disregard highly prevalent conditions such as IHD and 
conditions of clinical importance such as ‘gastro-oesophageal reflux disease’. After 
respective corrections of the index, we were able to comprehensively portray the 
comorbidity burden associated with ILDs. Moreover, this piece of research elucidated 
which comorbid conditions are especially sensitive to concepts of multiple coding 
(M2Q criterion) and prospective validation. 
Being aware of epidemiological burden, associations between comorbid conditions and 
outcomes of interest such as e.g. survival are of relevance for HSR to identify vital 
starting points for comprehensive patient management. In this regard, a simplified look 
at comorbidity prevalence per se is not sufficient to address associations concisely. It is 
even more important to raise awareness as to what extent the (pharmaceutical) treatment 
of comorbidity influences prognosis. In doing so, some kind of hierarchy which condi-
tions might be prioritized in case of multi-morbidity becomes feasible. Proceeding with 
the ILD example, it could be shown that IHD only had a detrimental association with 
survival if untreated, whereas treated IHD had no association with all-cause mortality 
(Schwarzkopf, Witt et al. 2018). 
Subsequently, the cost impact of distinct comorbid conditions should be quantified to 
reflect the economic burden on the individual, but also at the population level. Regard-
ing ILDs, the master thesis of Frank demonstrated that particularly comorbidities of low 
prevalence were highly cost driving (e.g. lung cancer), whereas highly prevalent 
comorbid conditions often had a limited cost impact (e.g. COPD) (Frank 2018).  
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As a further outlook, combining information on comorbidity prevalence with infor-
mation on cost impact opens the box for comprehensive budget impact analyses, which 
might also take age and gender aspects (potential for age- and gender-specific comor-
bidity and cost profiles) into account. Corresponding figures would be of utmost im-
portance to support evidence-based priority setting in comorbidity management. 
 
b. Structures of health care spending 
Claims data cover various aspects of health care service provision with inpatient care, 
outpatient care and drug prescriptions as the most relevant elements. In consequence, 
not only the expenditure level per se, but also the underlying structures can be reflected 
in cross-sectional and longitudinal analyses. Given that claims data often follow up an 
insurant over a period of several years, they have particular potential for incidence-
based cost of illness approaches that accumulate health care expenditures over the 
lifetime course of a disease (Tarricone 2006) or specific periods as exemplified in 
Schwarzkopf et al. 2015 (Schwarzkopf, Wacker et al. 2015).  
A necessary precondition in this regard is the realignment of costs of care with 
patient/individual follow-up periods because, other than for prevalence-based 
approaches (for an application see the COPD with(out) IHD study of Schwarzkopf et al.  
(Schwarzkopf, Wacker et al. 2016)), relying on accounting years is not feasible. 
Outpatient diagnoses are reported on a quarterly basis and, therefore, defining 
‘incidence’ not by date but by quarter yields the highest degree of precision. This 
operationalization was chosen for an exemplary study of ours that reports all-cause and 
disease-specific costs of care among lung cancer patients from the quarter of diagnosis 
over a patient-individual 3-year follow-up period (Schwarzkopf, Wacker et al. 2015). 
The corresponding analyses revealed costs per case of approximately €38,700 over the 
entire observation period. Just over half this amount was related to lung cancer 
treatment. Referring to disease-related costs, inpatient care was the main contributor 
followed by lung cancer-related drugs. This structure could be replicated within 
different treatment strata (surgery, chemo-/radiotherapy, no tumour-directed therapy), 
even though proportions and absolute amounts varied to some extent. 
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In addition to reporting costs per case, the longitudinal nature of claims data enables the 
detection of changes in the cost structure over time. Proceeding with the lung cancer 
example, domain-specific expenditures were also reported quarterwise over the entire 
patient-individual follow-up period.  
These analyses revealed that the initial 6 months post diagnosis accounted for more than 
two-fifths of all-cause costs per case, and for just half of lung cancer-related costs per 
case. After this initial peak, all-cause spending, lung cancer-related spending and the 
share of lung cancer-related spending in all cause-spending decreased over time. This 
effect was mainly driven by an abrupt decline in spending in the inpatient sector right 
after the quarter of diagnosis. The most probable explanation for this observation is that 
cost-intense surgical procedures were in general performed witin 6 months after 
diagnosis. Moreover, it became obvious that spending on lung cancer-related drugs 
increased in the initial phase post diagnosis but remained quite stable from the third 
quarter onwards. This might be related to the fact that, after the onset of 
chemotherapeutic interventions, corresponding treatment is provided continuously over 
an extended period of time. In the course of the disease, lung cancer-related drugs 
become the crucial component of disease-related costs because they exceed inpatient 
spending from the second year post diagnosis onwards (Schwarzkopf, Wacker et al. 
2015). 
These trends and shifts would have been masked if only aggregated costs per case had 
been evaluated. Indeed, this disaggregated perspective is a valuable contribution 
towards a better judgement on ‘common’ care pathways in the course of the disease. To 
further enhance the methodological quality of time trend analysis, and to allow 
investigations on the effect of potential impact factors over time (e.g. age, gender, 
morbidity), a standard application of techniques that account for intra-subject 
correlation (Fitzmaurice, Laird et al. 2011), such as generalized estimation equations 
(GEEs) (for an eapplication, see (Schwarzkopf, Hao et al. 2014)) and mixed models (for 
an application, see (Schwarzkopf, Holle et al. 2017)), is strongly recommended.  
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c. Subpopulation-specific display of health care service utilization pat-
tern 
As a key component of HSR, claims data not only include diagnoses and reimbursement 
information but incorporate detailed information on service provision within the SHI 
system. This opens the scope for in-depth hypothesis-driven comparisons of health care 
service provision between different patient populations. Here, aspects of equity in ac-
cess as well as on quality of care are of particular interest. Despite claims data not in-
cluding direct information on output and outcome, these aspects of care quality can be 
approximated with some creative efforts. 
An example in this regard is putting diagnostic information on complications (outcome) 
into context with data on provision of distinct medical services (input), as done within 
our study on diabetes care in community-living and institutionalized individuals with 
dementia (Schwarzkopf, Holle et al. 2017). Here, we contrasted the setting-specific 
conduct of guideline-recommended diabetes-relevant medical examinations as well as 
the occurrence of diabetes-related complications in community-dwellers and nursing 
home residents. The care level-stratified analyses unveiled a consistent trend towards 
less frequent controls of blood parameters and ocular background in the institutional 
setting. In parallel, we observed a rather heterogeneous picture regarding the occurrence 
of diabetes-related complications (Schwarzkopf, Schunk et al. 2014). Altogether, this 
piece of evidence reflects an initial example of how to (partially) appraise the effective-
ness of health care provision within claims data. Moreover, the findings at the popula-
tion level point to subpopulations that are in particular need of extended service provi-
sion. This modus operandi matches with the improvement-oriented character of HSR.  
As soon as subgroup differences in health care service utilization patterns are unveiled, 
subsequent explanatory analyses to identify the key impact factors on these differences 
are useful. Assuming that less aggressive end-of-life care (process) corresponds to pa-
tient preferences and thus indirectly enhances quality of life (outcome), we reflected 
aggressiveness of end-of-life care in lung cancer patients based on the receipt of distinct 
services (Walter, Tufman et al. 2018). To factor in potential inequity in service access 
between the rural and the urban setting, patient-individual zip codes were linked with 
official statistics from the ‘Bundesamt für Bauwesen und Raumordnung’ (i.e. ‘German 
Federal Institute for Research on Building, Urban Affairs, and Spatial Development’) to 
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classify the distinct residential areas correspondingly. The analyses substantiated evi-
dence on equity in service access for rural and urban populations with supportive care 
being in general capable of expansion. Moreover, the presence of distinct comorbid 
conditions and previous tumour-directed therapy were identified as the main triggering 
factors for differences regarding the structure of end-of-life care. 
To forge the bridge from population-level evidence on health care utilization to patient-
level care trajectories, longitudinal analyses that take advantage of the techniques of 
data mining and machine learning seem to be particular promising. A first descriptive 
step in this regard is a recent paper by Vogt and colleagues (Vogt, Scholz et al. 2018), 
who identified typical outpatient careers in individuals with heart failure via sequence 
clustering. Subsequently, these careers might be compared regarding their effectiveness 
(e.g. time to hospitalization) via the techniques outlined in Chapter 2a to derive best 
practice examples for advisable patient management strategies. 
 
 
4. Informative value of claims data to generate ‘real-world’ evi-
dence 
a. Relationship between claims data and other data sources 
To judge the informative value of claims data for evidence generation soundly, a dis-
cussion against other sources of evidence is of utmost importance. In HSR, these are 
particularly disease-specific registries and (in part) survey-based cohort studies. 
Referring to the example of haemophilia (Schopohl, Bidlingmaier et al. 2018), we could 
demonstrate that claims data outperform registries regarding economic research and 
comprehensive addressing of morbidity-related confounders. Moreover, they were clas-
sified as comparably well suited to reflect aspects of pharmacovigilance with in parallel 
substantial drawbacks in outcomes research (e.g. quality of life, short- and long-term 
clinical results). These findings seem by and large to be transferable to other indication 
areas where disease-specific registries exist (e.g. ILDs). This is also true for the conclu-
sion that some of the claims data-related limitations could be mitigated by further ad-
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vancements in the ICD coding system. Here, shifting the coding requirements to the re-
cently published ICD11 might be a step in the right direction. 
However, knowledge of different spectra of information compared with other sources of 
evidence is a necessary but not sufficient condition. All the more, therefore, further in-
sights on systematic differences between secondary data-based information and self-
reports on health care service utilization are paramount. Our comparison of survey-
reported health care utilization from the KORA cohort with external data from claims 
data and official statistics indicated a substantial amount of selection and recall bias 
(Hunger, Schwarzkopf et al. 2013). Particularly service utilization related to increased 
frailty of the user such as nursing care or inpatient treatment was found to be heavily 
underreported in self-reports. This piece of evidence can be considered as starting point 
for deriving age- and gender-specific correction factors for survey-based reports on 
health care service utilization. 
 
b. Claims data analyses as a tool for policy decision support 
Qualitative and quantitative details on comprehensiveness and representativeness of in-
formation derived from claims data create a vital basis for evaluating their prospects for 
evidence generation in support of reimbursement decisions.  
Particularly in the Anglo-American setting, it is common to not fully reimburse innova-
tive technologies right from market entry because there is a substantial amount of uncer-
tainty regarding health outcome, service utilization and long-term costs of care. Instead, 
further evidence on the technology of interest is collected in the real-world setting, and 
provider payment is linked to the performance of the technology. To do so, service pro-
viders and manufacturer conclude so-called managed entry agreement (MEA) contracts, 
where both parties agree on the conditions for full service coverage at a later point in 
time. The final decision is tied to the evaluation of the added value of the innovative 
technology in the routine care setting with corresponding evidence being collected dur-
ing the introduction phase (Hutton, Trueman et al. 2007, Stafinski, McCabe et al. 2010).  
Regarding the German SHI, MEAs are still of subordinate relevance. Since the Health 
Care Provision Act (GKV-Versorgungsstrukturgesetz) in 2011, the interest in such 
schemes has been growing because regulatory bodies opened the scope for selective 
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contracts with evidence development (§137e SGBV). For this evolving field, we elabo-
rated a generic value-based typology of MEAs (Brandes, Schwarzkopf et al. 2016). 
Subsequently, the contribution of claims data to the respective forms was appraised 
based on the criteria data availability, completeness, timeliness, confidentiality, reliabil-
ity and validity. These qualitative analyses revealed limited usefulness of claims data to 
target the safety aspects of a new technology, while acknowledging their substantial 
benefits regarding a reduction in uncertainty about the utilization and costs associated 
with a new technology. This typology might be a valuable supporting tool for SHIs that 
are not well versed yet with key success criteria for selective contracting. 
  
 
5. Concluding summary 
Having depicted the challenges of claims data in the context of HSR, this ‘Habilita-
tionsschrift’ has outlined their prospects for descriptive, analytical, and some extent 
quasi-experimental HSR with illustrative examples. To advocate the role of SHI claims 
data as a cornerstone of HSR in Germany, additional conceptual thoughts on their con-
tributions towards evidence generation for policy decision making were elaborated. 
Chapter 2 expounded prominent challenges for the design of claims data-based HSR 
studies and unveiled state of the art strategies to deal with these issues. In summary, tra-
ditional methods from epidemiological and public health statistics can be transferred to 
claims data analyses in many instances. To enhance precise patient classification, the 
application of internal validation techniques, e.g. the M2Q criterion, combined with 
prospective validation was recommended.  
Based on illustrative examples, Chapter 3 introduced ‘morbidity burden’, ‘budget im-
pact’ and ‘patient pathways’ as particularly promising fields of application for claims 
data-based HSR. As take home messages, this section emphasized the necessity to move 
to disease-specific adaptations of established measures of comorbidity burden, encour-
aged detailed disentangling of cost structures in the longitudinal view and provided 
suggestions for an operationalization of aspects related to quality of care.  
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Subsequently, Chapter 4 classified claims data as a valuable source for (early) evidence 
generation in economically oriented HSR and HSR in especially vulnerable populations.  
In summary, the work presented has emphasized that the use of claims data for ques-
tions of HSR is a vital challenge, because data are initially collected for the purpose of 
reimbursement. In consequence, the conduct of claims data-based HSR requires pro-
found knowledge of health care system-related framework conditions (and their changes 
over time) and clinical disease-specific expertise to ensure a scientifically sound inter-
pretation of the observed documentation patterns.  
In this regard, intense communication between data owners and external analysts in 
combination with early cooperation with clinical specialists enhances the quality of re-
search. Such multi-disciplinary cooperation promotes the case-by-case provision of data 
sets tailored to the research question of interest. Nevertheless, this cannot fully over-
come the generic issues of claims data-based research: first, the clients of a distinct SHI 
fund might not be representative of the resident German population. Second, the lack of 
clinical data (e.g. disease severity) and patient-reported outcomes (e.g. health-related 
quality of life) limit the scope for HSR. Referring to the input–throughput–output mod-
el, the strengths of claims data are ‘input’, but ‘process’ and ‘long-term result’ can only 
be addressed with great creative effort. However, these two components are crucial for 
sound support of policy decision makers.  
In addition, sound policy decision support requires scientific consensus on how to con-
duct and present claims data analyses. In this regard, national standards such as GPS 
and STROSA are a necessary initial step in the right direction but further harmonization 
beyond seems deeply required. There is great need for a common understanding on how 
to validate diagnoses, how to define disease incidence and how to operationalize dis-
ease-related costs of care. Moreover, the installation of some kind of permanent team 
that focuses on the prospects and strategies for the operationalization of patient-reported 
outcomes within claims data will mean significant progress. Finally, a careful adapta-
tion of current data protection laws that alleviates the linkage of information from dif-
ferent data sources (claims data, survey, registries), such as is possible in some Nordic 
countries, is indispensable in the long run to take full advantage of mutual synergies to 
foster patient-centred HSR. 
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